Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

SEER vs CDNA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SEER
Seer, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$105M
5Y Perf.-96.7%
CDNA
CareDx, Inc

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$1.11B
5Y Perf.-70.4%

SEER vs CDNA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SEER logoSEER
CDNA logoCDNA
IndustryBiotechnologyMedical - Diagnostics & Research
Market Cap$105M$1.11B
Revenue (TTM)$16M$413M
Net Income (TTM)$-79M$-8M
Gross Margin40.7%48.2%
Operating Margin-5.2%-3.3%
Forward P/E22.8x
Total Debt$26M$20M
Cash & Equiv.$41M$65M

SEER vs CDNALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SEER
CDNA
StockDec 20May 26Return
Seer, Inc. (SEER)1003.3-96.7%
CareDx, Inc (CDNA)10029.6-70.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: SEER vs CDNA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CDNA leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Seer, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SEER
Seer, Inc.
The Income Pick

SEER is the clearest fit if your priority is income & stability and growth exposure.

  • beta 0.84
  • Rev growth -8.1%, EPS growth -3.0%, 3Y rev CAGR 29.7%
  • Lower volatility, beta 0.84, Low D/E 7.9%, current ratio 16.53x
Best for: income & stability and growth exposure
CDNA
CareDx, Inc
The Long-Run Compounder

CDNA carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 385.1% 10Y total return vs SEER's -96.7%
  • 13.8% revenue growth vs SEER's -8.1%
  • -2.0% margin vs SEER's -486.0%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthCDNA logoCDNA13.8% revenue growth vs SEER's -8.1%
Quality / MarginsCDNA logoCDNA-2.0% margin vs SEER's -486.0%
Stability / SafetySEER logoSEERBeta 0.84 vs CDNA's 1.39
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)CDNA logoCDNA+45.2% vs SEER's +1.6%
Efficiency (ROA)CDNA logoCDNA-1.9% ROA vs SEER's -25.7%, ROIC -5.7% vs -21.3%

SEER vs CDNA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SEERSeer, Inc.
FY 2023
Grant
100.0%$1M
CDNACareDx, Inc
FY 2025
Service
85.0%$274M
Product
15.0%$48M

SEER vs CDNA — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCDNALAGGINGSEER

Income & Cash Flow (Last 12 Months)

CDNA leads this category, winning 6 of 6 comparable metrics.

CDNA is the larger business by revenue, generating $413M annually — 25.3x SEER's $16M. Profitability is closely matched — net margins range from -2.0% (CDNA) to -4.9% (SEER). On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSEER logoSEERSeer, Inc.CDNA logoCDNACareDx, Inc
RevenueTrailing 12 months$16M$413M
EBITDAEarnings before interest/tax-$76M$2M
Net IncomeAfter-tax profit-$79M-$8M
Free Cash FlowCash after capex-$46M$65M
Gross MarginGross profit ÷ Revenue+40.7%+48.2%
Operating MarginEBIT ÷ Revenue-5.2%-3.3%
Net MarginNet income ÷ Revenue-4.9%-2.0%
FCF MarginFCF ÷ Revenue-2.8%+15.8%
Rev. Growth (YoY)Latest quarter vs prior year+4.5%+39.0%
EPS Growth (YoY)Latest quarter vs prior year+8.6%+126.3%
CDNA leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

CDNA leads this category, winning 2 of 3 comparable metrics.
MetricSEER logoSEERSeer, Inc.CDNA logoCDNACareDx, Inc
Market CapShares × price$105M$1.1B
Enterprise ValueMkt cap + debt − cash$90M$1.1B
Trailing P/EPrice ÷ TTM EPS-1.35x-53.60x
Forward P/EPrice ÷ next-FY EPS est.22.85x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue7.52x2.92x
Price / BookPrice ÷ Book value/share0.36x3.77x
Price / FCFMarket cap ÷ FCF30.66x
CDNA leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

CDNA leads this category, winning 8 of 8 comparable metrics.

CDNA delivers a -2.6% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-29 for SEER. CDNA carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to SEER's 0.08x. On the Piotroski fundamental quality scale (0–9), CDNA scores 5/9 vs SEER's 4/9, reflecting solid financial health.

MetricSEER logoSEERSeer, Inc.CDNA logoCDNACareDx, Inc
ROE (TTM)Return on equity-29.2%-2.6%
ROA (TTM)Return on assets-25.7%-1.9%
ROICReturn on invested capital-21.3%-5.7%
ROCEReturn on capital employed-25.9%-5.8%
Piotroski ScoreFundamental quality 0–945
Debt / EquityFinancial leverage0.08x0.06x
Net DebtTotal debt minus cash-$15M-$46M
Cash & Equiv.Liquid assets$41M$65M
Total DebtShort + long-term debt$26M$20M
Interest CoverageEBIT ÷ Interest expense
CDNA leads this category, winning 8 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

CDNA leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CDNA five years ago would be worth $2,759 today (with dividends reinvested), compared to $494 for SEER. Over the past 12 months, CDNA leads with a +45.2% total return vs SEER's +1.6%. The 3-year compound annual growth rate (CAGR) favors CDNA at 37.7% vs SEER's -19.2% — a key indicator of consistent wealth creation.

MetricSEER logoSEERSeer, Inc.CDNA logoCDNACareDx, Inc
YTD ReturnYear-to-date+3.3%+12.0%
1-Year ReturnPast 12 months+1.6%+45.2%
3-Year ReturnCumulative with dividends-47.2%+161.1%
5-Year ReturnCumulative with dividends-95.1%-72.4%
10-Year ReturnCumulative with dividends-96.7%+385.1%
CAGR (3Y)Annualised 3-year return-19.2%+37.7%
CDNA leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SEER and CDNA each lead in 1 of 2 comparable metrics.

SEER is the less volatile stock with a 0.84 beta — it tends to amplify market swings less than CDNA's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.3% from its 52-week high vs SEER's 78.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSEER logoSEERSeer, Inc.CDNA logoCDNACareDx, Inc
Beta (5Y)Sensitivity to S&P 5000.84x1.39x
52-Week HighHighest price in past year$2.41$23.24
52-Week LowLowest price in past year$1.65$10.96
% of 52W HighCurrent price vs 52-week peak+78.0%+92.3%
RSI (14)Momentum oscillator 0–10049.856.4
Avg Volume (50D)Average daily shares traded401K667K
Evenly matched — SEER and CDNA each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates SEER as "Hold" and CDNA as "Buy".

MetricSEER logoSEERSeer, Inc.CDNA logoCDNACareDx, Inc
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$24.00
# AnalystsCovering analysts413
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+11.3%+7.9%
Insufficient data to determine a leader in this category.
Key Takeaway

CDNA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.

Best OverallCareDx, Inc (CDNA)Leads 4 of 6 categories
Loading custom metrics...

SEER vs CDNA: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is SEER or CDNA a better buy right now?

For growth investors, CareDx, Inc (CDNA) is the stronger pick with 13.

8% revenue growth year-over-year, versus -8. 1% for Seer, Inc. (SEER). Analysts rate CareDx, Inc (CDNA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — SEER or CDNA?

Over the past 5 years, CareDx, Inc (CDNA) delivered a total return of -72.

4%, compared to -95. 1% for Seer, Inc. (SEER). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus SEER's -96. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — SEER or CDNA?

By beta (market sensitivity over 5 years), Seer, Inc.

(SEER) is the lower-risk stock at 0. 84β versus CareDx, Inc's 1. 39β — meaning CDNA is approximately 66% more volatile than SEER relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 8% for Seer, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — SEER or CDNA?

By revenue growth (latest reported year), CareDx, Inc (CDNA) is pulling ahead at 13.

8% versus -8. 1% for Seer, Inc. (SEER). On earnings-per-share growth, the picture is similar: Seer, Inc. grew EPS -3. 0% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, SEER leads at 29. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — SEER or CDNA?

CareDx, Inc (CDNA) is the more profitable company, earning -5.

6% net margin versus -620. 9% for Seer, Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNA leads at -5. 5% versus -717. 7% for SEER. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — SEER or CDNA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is SEER or CDNA better for a retirement portfolio?

For long-horizon retirement investors, Seer, Inc.

(SEER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Both have compounded well over 10 years (SEER: -96. 7%, CDNA: +385. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between SEER and CDNA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

SEER

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 24%
Run This Screen
Stocks Like

CDNA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 28%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SEER and CDNA on the metrics below

Revenue Growth>
%
(SEER: 4.5% · CDNA: 39.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.